Novartis Institutes for BioMedical Research
250 Mass Avenue
About Novartis Institutes for BioMedical Research
Novartis Institutes for BioMedical Research Headquarters: Cambridge, Massachusetts, USA. Global sites include: Basel, Switzerland; Emeryville and La Jolla, California, USA; East Hanover, New Jersey, USA; Fort Worth, Texas, USA; Horsham, UK; Shanghai, China; Singapore; and Siena, Italy.
Approximately 6,000 worldwide.
The Novartis Institutes for BioMedical Research (NIBR) is the global pharmaceutical research organization for Novartis committed to discovering innovative medicines to treat diseases with high unmet medical need. With more than 6,000 scientists and physicians around the world, our open and entrepreneurial culture encourages collaboration as we work to push the boundaries of science to change the practice of medicine. NIBR takes a unique approach to pharmaceutical research. At the earliest stages, research priorities are determined by patient need and disease understanding. Scientists and physicians at NIBR have broken down the boundaries between research and clinical practice and collaborate at the earliest stages of the R&D process. We believe we can better answer the demand for safer, more effective medicines by keeping our sights on both the science and the patient. To do this we use Proof-of-Concept (PoC) clinical trials, small-scale studies in well-defined patient groups used to get an early read-out on a drug’s safety and effectiveness. These studies help us find and advance the most promising drug candidates.
The Novartis clinical pipeline, which has consistently been ranked as one of the strongest in the industry, holds a broad stream of more than 100 new medicines in all stages of development. Our model of research – connecting the laboratory to the clinic, and pursuing molecular pathways across multiple diseases – means that we have to be a highly collaborative organization. Every project is made up of cross-functional teams, drawn from pathways scientists, chemists, disease area specialists, biologists, pharmacologists, clinicians and more. It is a way of working that has become a part of our research culture.
Diversity makes a difference. Innovation is enabled by a diversity of expertise, perspectives and ideas from people with different cultural backgrounds and professional experiences. By fostering diversity in the NIBR workplace, we continue to strengthen a culture that is entrepreneurial, open and inclusive.
We consider Diversity and Inclusion to encompass ethnicity, nationality, gender, sexual orientation, age, physical ability, religion and belief, thinking styles, education, life and professional experiences.
Main Recruitment Areas
In our Disease Areas, we are committed to understanding the underlying molecular basis of disease, which has enabled us to deepen our knowledge, and turn scientific insights into medical breakthroughs.
BS through PhD degree in science with focus on Biology, Chemistry, and Biochemistry.
10 articles with Novartis Institutes for BioMedical Research
8/3/2018Navitor Pharmaceuticals, headquartered in Cambridge, Massachusetts, announced that Thomas E. Hughes will be the company’s new chief executive officer.
The Novartis Institutes for BioMedical Research (NIBR) is ending its early-stage anti-infectives research programs located in Emeryville, California. As a result, the company expects to lay off about 140 employees.
Educational institutions, even at the high school level, are creating specialized biotechnology training programs to satisfy the growth they see within the biotech industry.
Novartis has found its new chief of oncology.
The company said the Breakthrough Therapy Designation is based on positive results from the Phase III MONALEESA-7 trial.
The scientist was among the nearly one dozen people injured on Oct. 31.
Novartis Institutes for BioMedical Research Cambridge Campus Wins Special Recognition In Lab Of The Year Awards
Ash Stevens Honors Cancer Research Award Winner - James E. Bradner, MD, Novartis Institutes for BioMedical Research
Drug-Resistant Melanoma Tumors Shrink When Therapy Is Interrupted, University of California, San Francisco (UCSF), Novartis Institutes for BioMedical Research, and University Hospital Zurich Study